The promise of precision medicine as a model to customize health care to the individual patient is heavily dependent upon new genetic tools to classify and characterize diseases and their hosts. Liquid biopsies serve as a safe alternative to solid biopsies and are thus a useful and critical component to fully realizing personalized medicine. The International Liquid Biopsy Standardization Alliance (ILSA) comprises organizations and foundations that recognize the importance of working towards the global use of liquid biopsy in oncology practice to support clinical decision making and regulatory considerations and seek to promote it in their communities. This manuscript provides an overview of the independent liquid biopsy- and standardization-based programs engaged with ILSA, their objectives and progress to date, and the tools and resources each is developing to contribute to the field. It also describes the unique areas of effort as well as synergy found within the group.

Biomarkers Consortium Cancer Steering Committee United States

BloodPAC United States

Cancer ID Czech Republic

CCS Associates Inc United States

Centro GENyO International Society of Liquid Biopsy United States

European Liquid Biopsy Society Germany

FNIH ctDNA QCM Project United States

Foundation for the National Institutes of Health United States

Friends of Cancer Research United States

Medical Device Innovation Consortium United States

National Institute for Biological Standards and Control UK

Northwestern Medicine International Society of Liquid Biopsy United States

University of Maryland Medical Center International Society of Liquid Biopsy United States

Citace poskytuje Crossref.org

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance